Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | FDPS | P14324 | 2/20 | 0.33 |
| ▸ | ENO1 | P06733 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL831709 | 0.88 | PRKCA (0.44) | LAP3CYP2C19CYP2D6CYP2C9LPAR3 | |
| SCHEMBL5961220 | 0.81 | LAP3 (0.37) | LAP3MEN1KMT2ALMNAHPGD | |
| SCHEMBL1327181 | 0.77 | LMNA (0.42) | LAP3MEN1KMT2ALMNAHPGD | |
| SCHEMBL11517632 | 0.76 | LPAR3 (0.41) | LMNATDP1CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL19347004 | 0.74 | MEN1 (0.37) | LAP3MEN1KMT2ALMNAHPGD | |
| SCHEMBL7836561 | 0.74 | MEN1 (0.37) | LAP3MEN1KMT2ALMNAHPGD | |
| SCHEMBL7822278 | 0.74 | LPAR3 (0.54) | LMNALPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL6785594 | 0.74 | MEN1 (0.48) | MEN1KMT2ALMNATDP1CYP2C19 | |
| SCHEMBL10553245 | 0.74 | MAPT (0.48) | MEN1KMT2ALMNAHPGDTSHR | |
| SCHEMBL233484 | 0.74 | MGAM (0.43) | MEN1KMT2ALMNATSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3145944-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10392422-B2 | Macrocyclic broad spectrum antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-10351595-B2 | — | — | 2019-07-16 | — | — | US | disclosed |
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| EP-3145944-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX Pharmaceuticals, Inc. (US) | 2017-03-29 | — | — | EP | disclosed |
| WO-2015179441-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| US-8586594-B2 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBVIE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2117526-B1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBOTT LAB (US) | 2013-04-03 | — | — | EP | disclosed |
| US-20120238581-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBVIE INC. | 2012-09-20 | — | — | US | disclosed |
| US-8258126-B2 | Vitamin D3 analogues for the prevention and treatment of bone disorders | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2012-09-04 | — | — | US | disclosed |
| US-20080032955-A1 | VITAMIN D3 ANALOGUES FOR THE PREVENTION AND TREATMENT OF BONE DISORDERS | K.U. LEUVEN RESEARCH AND DEVELOPMENT (BE) | 2008-02-07 | — | — | US | disclosed |
| EP-1809599-A1 | VITAMIN D3 ANALOGUES FOR THE PREVENTION AND TREATMENT OF BONE DISORDERS | K.U.Leuven Research & Development (BE) | 2007-07-25 | — | — | EP | disclosed |
| US-7118694-B2 | Compositions containing silicates and ion-conducting films containing the same | BASF AKTIENGESELLSCHAFT (DE) | 2006-10-10 | — | — | US | disclosed |
| WO-2006039763-A1 | VITAMIN D3 ANALOGUES FOR THE PREVENTION AND TREATMENT OF BONE DISORDERS | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2006-04-20 | — | — | WO | disclosed |
| US-20020160270-A1 | Compositions suitable for the use in electrochromic windows | BRONSTERT BERND (DE) | 2002-10-31 | — | — | US | disclosed |
| US-20020155353-A1 | Composition containing silicates | BRONSTERT BERND (DE) | 2002-10-24 | — | — | US | disclosed |
| US-6416905-B1 | 1 TO 95% BY WEIGHT OF A SOLID, HAVING A PRIMARY PARTICLE SIZE OF 5 NM TO 20 MICRONS, AND A POLYMER; ELECTROLYTIC CELL | BASF AKTIENGESELLSCHAFT (DE) | 2002-07-09 | — | — | US | disclosed |
| EP-0711773-B1 | HYMENIALDISINE AND DERIVATIVE THEREOF, PROCESS FOR PRODUCING INTERMEDIATE FOR SYNTHESIZING THE SAME, AND SAID INTERMEDIATE | SUNTORY LTD (JP) | 2001-09-12 | — | — | EP | disclosed |
| US-5621099-A | CARDIOVASCULAR DISORDERS | SUNTORY LIMITED (JP) | 1997-04-15 | — | — | US | disclosed |
| EP-0711773-A1 | HYMENIALDISINE AND DERIVATIVE THEREOF, PROCESS FOR PRODUCING INTERMEDIATE FOR SYNTHESIZING THE SAME, AND SAID INTERMEDIATE | SUNTORY LIMITED (JP) | 1996-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238581-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | DGAT1, DGAT2, LCAT | LAP3 1583/4885MEN1 2282/4885KMT2A 1509/4885 |
| US-10351595-B2 | — | MRPL21, PRSS1, PEPD | LAP3 219/4885MEN1 3458/4885KMT2A 4084/4885 |
| US-10392422-B2 | Macrocyclic broad spectrum antibiotics | MRPL21, PEPD, CTSC | LAP3 382/4885MEN1 2531/4885KMT2A 3283/4885 |
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | LAP3 382/4885MEN1 2531/4885KMT2A 3283/4885 |
| US-20080032955-A1 | VITAMIN D3 ANALOGUES FOR THE PREVENTION AND TREATMENT OF BONE DISORDERS | VDR, CYP24A1, CYP2R1 | LAP3 933/4885MEN1 1012/4885KMT2A 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.